GINKGO BIOWORKS HOLDINGS, INC.

DNA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-312.8M $-547.0M $-892.9M $-2.10B $-1.83B $-126.6M $-119.3M
Depreciation & Amortization $59.0M $63.0M $70.5M $42.6M $29.1M $13.9M $10.8M
Depreciation $40.3M $45.0M $54.8M $36.9M $26.9M $12.6M $9.6M
Amortization $18.7M $18.0M $15.7M $5.6M $1.2M $500.0K $500.0K
Stock-Based Compensation $81.5M $112.3M $229.9M $1.93B $1.61B $476.0K $771.0K
Net Cash from Operating Activities $-171.1M $-319.6M $-295.5M $-252.2M $-253.8M $-135.8M $-44.7M
Investing Activities
Capital Expenditures $7.7M $62.5M $40.8M $52.3M $56.5M $57.8M $22.2M
Business Acquisitions $0 $5.4M $0 $-82.4M $12.0M $0
Net Cash from Investing Activities $-240.3M $-62.2M $-80.7M $-67.4M $-73.3M $-67.1M $-74.6M
Financing Activities
Dividends Paid
Stock Repurchases $408.0K
Net Cash from Financing Activities $17.8M $-1.7M $-3.2M $95.3M $1.53B $90.3M $410.4M
Net Change in Cash $-393.4M $-383.8M $-380.0M $-223.3M $1.21B $-112.6M $291.1M
Free Cash Flow $-178.7M $-382.1M $-336.3M $-304.5M $-310.3M $-193.7M $-66.9M
Benjamin Graham

The stock investor is neither right or wrong because others agreed or disagreed with him; he is right because his facts and analysis are right.